Logo
Login
$BIOA
$5.47 +$0.48 (9.62%) Close

Company Executives

$BIOA Management Team

Dr. Dov Goldstein

Chief Financial Officer

Age 57
Compensation -
Sex Male

Dr. Eric Morgen

Chief Operating Officer

Director

Age 42
Compensation $2.465M USD
Sex Male

Dr. Paul Rubin

Chief Medical Officer

Age 71
Compensation $1.924M USD
Sex Male

Dr. Jean-Pierre Garnier

Independent Chairman of the Board

Age 77
Compensation $1.490M USD
Sex Male

Dr. Kristen Fortney

President

Chief Executive Officer

Director

Age 42
Compensation $12.23M USD
Sex Female

Board of Directors

From the proxy statement filed Apr 21, 2026
Directors
8
serving now
Independent
0 of 2
stated in the proxy; 6 not stated
Average tenure
5.2 years
from year joined
CEO also chairs the board
No
Jean-Pierre Garnier
Director Age On board Independent Committees Other public boards 2025 pay Source
Patrick Enright
64 2024
2 years
 Not stated
Audit Committee
Vera Therapeutics, Inc., Jazz Pharmaceuticals plc, Zenas BioPharma, Inc., Veradermics, Incorporated $129,252
James I. Healy
61 2024
2 years
 Not stated
Compensation Committee Nominating and Governance Committee · Chair
ArriVent Biopharma, Inc., Rapport Therapeutics, Inc. Not stated
Rekha Hemrajani
56 2021
5 years
 Not stated
Audit Committee · Chair Nominating and Governance Committee
ALX Oncology Holdings Inc. $141,752
Kristen Fortney
CEO
 43 2015
11 years
 Not independent None stated None stated Paid as CEO
Eric Morgen
Executive officer
 43 2017
9 years
 Not independent None stated None stated Not stated
Vijay Pande
55 2017
9 years
 Not stated
Audit Committee
None stated Not stated
Michael Davidson
69 2024
2 years
 Not stated
Compensation Committee · Chair Nominating and Governance Committee
Tenax Therapeutics, Inc. $138,752
Jean-Pierre Garnier
Board chair
 78 2024
2 years
 Not stated
Compensation Committee Nominating and Governance Committee
Carrier Global Corporation Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 21, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans